Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
4(40%)

Phase Distribution

Ph phase_4
3
30%
Ph not_applicable
1
10%
Ph phase_1
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (44.4%)
Phase 31 (11.1%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

terminated440%
completed660%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_4

China Post-marketing Surveillance (PMS) Study of Aldurazyme®

NCT05134571
completedphase_3

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

NCT06406153
terminatedphase_4

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

NCT00418821
completedphase_1

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

NCT01173016
terminated

Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome

NCT01572636
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05134571Phase 4

China Post-marketing Surveillance (PMS) Study of Aldurazyme®

Completed
NCT06406153Phase 3

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Completed
NCT00418821Phase 4

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

Terminated
NCT01173016Phase 1

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

Completed
NCT01572636

Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome

Terminated
NCT00852358Not Applicable

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Completed
NCT00741338Phase 1

Immune Tolerance Study With Aldurazyme® (Laronidase)

Completed
NCT00144768Phase 4

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Completed
NCT00215527Phase 1

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Terminated
NCT00786968Phase 1

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10